TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31783004
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 3.6 mL of articaine with 2 mL of dexamethasone (8‐mg/mL solution)
Study: 31783004
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 3.6 mL of articaine mixed with 2 mL of saline solution
Study: 21267039
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic (lidocaine 0.5% 10 mL)
Study: 21267039
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 9 mL of 0.5% lidocaine mixed with 1 mL of steroid (either betamethasone [6 mg] or methylprednisolone [40 mg])
Study: 17339189
Drug: Autologous peripheral
Normalized name: Autologous peripheral blood-derived CD34+ cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous peripheral blood stem cell transplantation (PBSCT) after induction and consolidation chemotherapy with BAVC regimen.
Study: 17339189
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with mitoxantrone, etoposide, and cytarabine (MICE) with or without G-CSF; consolidation therapy with mini-ICE.
Study: 14668149
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (EMG biofeedback training plus conventional exercise programme)
Study: 7922793
Drug: Injectable calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable calcitonin analogue ASC 710 (0.2 mg)
Study: 7922793
Drug: Oral ASC
Normalized name: ASC-618
DrugBank: ASC-618 (DB18423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ASC 710 (20 mg)
Study: 29151561
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment in community centers (n=29)
Study: 23968366
Drug: Structured lifestyle
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured lifestyle and medication treatment by practice nurses with additional self‐monitoring
Study: 23968366
Drug: Structured lifestyle
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured lifestyle and medication treatment by practice nurses without additional self‐monitoring
Study: 23968366
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of or dose change in lipid lowering or antihypertensive medications
Study: 19100928
Drug: Continuous bladder
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bladder catheterization (Group CC; n = 100)
Study: 12769155
Drug: 2% polyvinylpyrrolidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% polyvinylpyrrolidone (PVP) solution
Study: 7517239
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution
Study: 11081985
Drug: Standardized extract
Normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang) taken three times daily for a minimum of 3 days and a maximum of 8 days (pilot study) or for exactly three days (phase III study)
Study: 11081985
Drug: Standardized extract
Normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized extract (SHA-10) of Andrographis paniculata fixed combination (Kan jang)
Study: 10801250
Drug: Tamsulosin 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.6 mg
Study: 9352698
Drug: Tamsulosin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (all doses)
Study: 4037540
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg bolus followed by continuous infusion)
Study: 26995374
Drug: Metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 25 to 100 mg BID
Study: 17727860
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg/day
Study: 17727860
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Atorvastatin (crossover treatment)
Study: 15851919
Drug: bivalent rgp120
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rgp120 vaccine
Study: 10799382
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg) with low-fat spread
Study: 10799382
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (50 mg) with high-fat spread
Study: 10799382
Drug: Alpha- plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha- plus beta-carotene (8 mg) with low-fat spread
Study: 10799382
Drug: Alpha- plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha- plus beta-carotene (8 mg) with high-fat spread
Study: 10799382
Drug: Lutein esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein esters (8 mg lutein) with low-fat spread
Study: 10799382
Drug: Lutein esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein esters (8 mg lutein) with high-fat spread
Study: 3904886
Drug: Indalpine 150
Normalized name: Indalpine
DrugBank: Indalpine (DB08953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indalpine 150 mg per day
Study: 3904886
Drug: Mianserin 60
Normalized name: mianserin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 60 mg per day
Study: 30105510
Drug: Lusutrombopag 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag 2 mg once daily for 7 days
Study: 30105510
Drug: Lusutrombopag 3
Normalized name: lusutrombopag 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag 3 mg once daily for 7 days
Study: 30105510
Drug: Lusutrombopag 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag 4 mg once daily for 7 days
Study: 26704258
Drug: Epidural Cortical
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Cortical Stimulation (CS) combined with intensive language therapy (3 hours a day for 6 weeks)
Study: 26704258
Drug: Epidural Cortical
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Cortical Stimulation (CS) combined with intensive language therapy
Study: 20103451
Drug: Discount coupon
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discount coupon for oral contraceptive pills (OCPs)
Study: 11152898
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (800 mg) and topical benzocaine (20%)
Study: 11152898
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and topical benzocaine (20%)
Study: 11152898
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (800 mg) and topical placebo
Study: 11152898
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo and topical placebo
Study: 7981922
Drug: Investigated drugs
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigated drugs
Study: 31494028
Drug: Morphine Parent/Nurse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine Parent/Nurse Controlled Analgesia (PNCA)
Study: 31494028
Drug: Continuous Opioid
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Opioid Infusion (COI)
Study: 24748338
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg tablets, twice per week for 12 weeks)
Study: 24748338
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist (decapeptyl, 3.75 mg subcutaneous, single injection, once a month for 3 months)
Study: 15334276
Drug: Ciclopirox (Loprox)
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox (Loprox) gel
Study: 9024265
Drug: Cyclical hPTH-(1-34)
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical hPTH-(1-34) + sequential calcitonin (75 U/day)
Study: 27394381
Drug: Routine low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine low dose aspirin (LDA) 75 mg once daily from first trimester until 36-week gestation
Study: 24495314
Drug: Gemigliptin/metformin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in high-fat fed state
Study: 24495314
Drug: Gemigliptin/metformin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin/metformin sustained-release fixed-dose combination tablet (25/500 mg x 2 tablets) in fasted state
Study: 8634878
Drug: Acrivastine 8
Normalized name: acrivastine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine 8 mg + pseudoephedrine 60 mg (A + P)
Study: 6378232
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (100 mg/day)
Study: 30898204
Drug: Testosterone (1%)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (1%) gel for 12 weeks
Study: 27128212
Drug: Tofacitinib (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (0.1, 0.3, 1, 3, 10, 30, 60, and 100 mg)
Study: 10884257
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.3 mg/kg)
Study: 22097138
Drug: Xiaozhong Zhitong
Normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaozhong Zhitong mixture (50 ml every time, twice a day for 4 weeks)
Study: 22097138
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg every time, twice a day)
Study: 22097138
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (no preventing treatment)
Study: 19186712
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy combined with tropisetron (5 mg daily for 6 days)
Study: 19186712
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture combined with tropisetron (5 mg daily for 6 days)
Study: 8832449
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine with D = 1 mg, LI = 6 min (Group 1‐6)
Study: 8832449
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine with D = 1.5 mg, LI = 9 min (Group 1.5‐9)
Study: 8832449
Drug: PCA morphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA morphine with D = 2 mg, LI = 12 min (Group 2‐12)
Study: 8310977
Drug: Amlodipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (mean daily dose 8.8 mg)
Study: 8310977
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean daily dose 83.7 mg)
Study: 30725077
Drug: Youth‐Nominated Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth‐Nominated Support Team Intervention (YST) plus Treatment as Usual (TAU)
Study: 30004900
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion (ILE) 5.25 mL/kg
Study: 17342480
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg once daily for 7 days
Study: 8632075
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 7 days
Study: 17342480
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg combined with itraconazole 200 mg once daily for 7 days
Study: 16359503
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg day(-1)
Study: 11824492
Drug: Single-family behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-family behavioral family therapy (BFT)
Study: 9551874
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg-360 mg
Study: 28142344
Drug: NTS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTS group (three-site injection technique)
Study: 28142344
Drug: SSI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSI group (single-site injection technique)
Study: 26429605
Drug: Vancomycin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (mean 12.8 mg/kg every 12 hours for 7 patients, every 8 hours for 1 patient, every 24 hours for 1 patient)
Study: 21603891
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg) + Ethanol (0.3 g/kg)
Study: 7904786
Drug: Ethanol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.3 g/kg)
Study: 21603891
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg) + Ethanol (0.6 g/kg)
Study: 21603891
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug conditions (Oxycodone and Ethanol)
Study: 19394894
Drug: Lapatinib 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500 mg once daily
Study: 18458039
Drug: Lapatinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 500 mg twice daily
Study: 18458039
Drug: Lapatinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (both dosing schedules)
Study: 12973963
Drug: Propofol alone
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol alone (1.5 mg/kg)
Study: 12973963
Drug: Combined propofol-sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined propofol-sevoflurane (1.5 mg/kg propofol followed by 5% sevoflurane in oxygen)
Study: 9223888
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 3 l.min‐1 oxygen via a mask for initial 3 hours
Study: 8429447
Drug: Beclomethasone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (50 micrograms nebulized, 3 doses per day for 28 days)
Study: 8429447
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo, 3 doses per day for 28 days)
Study: 31868565
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea cream
Study: 30415610
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (15 to 20 mg weekly)
Study: 27922745
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg q.12h
Study: 27922745
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg q.8h
Study: 24949292
Drug: Heparin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1000 IU)
Study: 14738234
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (18 microg)
Study: 6105907
Drug: Flunitrazepam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.05 mg . kg‐1
Study: 6105907
Drug: Thiopentone 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 6.0 mg . kg‐1
Study: 28045137
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum TIFN101
Study: 28045137
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum WCFS1
Study: 28045137
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum CIP104448
Study: 23953270
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR (400-800 mg)
Study: 23953270
Drug: risperidone (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (2-6 mg)
Study: 19639375
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 50 microg x kg(‐1) x min(‐1)
Study: 19639375
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 100 microg x kg(‐1) x min(‐1)
Study: 19639375
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 150 microg x kg(‐1) x min(‐1)
Study: 19639375
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate of 120 microg x kg(‐1) x min(‐1)
Study: 19639375
Drug: Predicted infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Predicted infusion rate to achieve a mean concentration of 5 microg x mL(‐1)
Study: 16798042
Drug: Doxycycline-rifampin-amikacin (ADR)
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doxycycline-rifampin-amikacin (ADR) regimen: doxycycline 100 mg twice a day, rifampin 10 mg/kg body weight/day every morning for eight weeks, plus 7.5 mg/kg amikacin intramuscularly twice a day for seven days.
Study: 16798042
Drug: Doxycycline-rifampin (DR)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline-rifampin (DR) regimen: doxycycline 100 mg twice a day and rifampin 10 mg/kg body weight/day every morning for eight weeks.
Study: 11896119
Drug: Bolus doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doxorubicin (30 mg/m2 every 3 weeks for a total of 360 mg/m2)
Study: 11896119
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of doxorubicin (360 mg/m2 over 48 hours)
Study: 11896119
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Bolus and Continuous infusion)
Study: 23084955
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET)
Study: 31044235
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg moxidectin
Study: 31044235
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg moxidectin
Study: 31044235
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg moxidectin plus 400 mg albendazole
Study: 31044235
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg moxidectin plus 400 mg albendazole
Study: 31044235
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg moxidectin plus 400 mg albendazole
Study: 24149557
Drug: Dance exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dance exercise (twice a week for 6 months)
Study: 19349290
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (70 g/d; containing 420 micromol of SF precursor) for 8 weeks
Study: 15204158
Drug: Acitretin 25-50
Normalized name: acitretin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 25-50 mg/day for 1 month
Study: 15204158
Drug: Conventional topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional topical treatment (betamethasone/salicylic acid ointment)
Study: 9839766
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl (10 mg day(-1)) administered for 19 consecutive days with a single dose of warfarin (25 mg) on day 14.
Study: 9839766
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) administered alone on day 14 after an initial 13-day period with no medication.
Study: 9839766
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl (10 mg day(-1)) administered for 19 days with an additional single dose of warfarin (25 mg) on day 41 after a washout period.
Study: 7648286
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 120 J/cm2 laser light (n = 5)
Study: 7648286
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 70 J/cm2 laser light (n = 4)
Study: 7648286
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg
Study: 70947
Drug: Oxatimide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatimide (20 mg, two tablets three times a day for 2 weeks)
Study: 26190853
Drug: Four positions
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four positions for intratracheal beractant administration (Group I)
Study: 26190853
Drug: Two positions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two positions for intratracheal beractant administration (Group II)
Study: 26190853
Drug: Neutral position
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral position for intratracheal beractant administration (Group III)